Tilray Medical Announces Positive Results from Study on Oral
Cannabis Extract for Chemotherapy-Induced Emesis
SYDNEY, Australia, Nov. 07, 2024 (GLOBE
NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc.
("Tilray Brands") (NASDAQ: TLRY and TSX: TLRY) and a global leader
in medical cannabis empowering the therapeutic alliance between
patients and healthcare practitioners to make informed
individualized health decisions, is pleased to announce the final
results of a new scientific study their team has supported titled,
"Oral Cannabis Extract for Secondary Prevention of
Chemotherapy-Induced Nausea and Vomiting (CINV)."
This randomized, placebo-controlled trial aimed
to test the effectiveness of an oral cannabis extract in adults
suffering from CINV despite standard anti-nausea treatments.
Participants received capsules containing 2.5 mg of THC and 2.5 mg
of CBD or a placebo, taken three times daily for six days.
From 2016 to 2022, 147 participants were
recruited. The study found that the cannabis extract significantly
improved the rate of complete response—meaning no vomiting or use
of additional medications—from 8% with placebo to 24% with THC:
CBD. Other benefits included reduced nausea and fewer daily vomits.
However, some side effects were noted, such as sedation (18% vs.
7%), dizziness (10% vs. 0%), and transient anxiety (4% vs. 1%).
Denise Faltischek, Chief Strategy Officer, and
Head of International at Tilray Brands, said, “These findings are
encouraging for cancer patients undergoing chemotherapy. This study
is a crucial step in improving patient care and quality of life.”
She continued, "Our involvement in this study underscores our
commitment to advancing medical research. The positive outcomes
highlight the potential of cannabinoids for managing CINV."
Tilray Medical continues to transform lives by
providing access to medical cannabis. Tilray is a leading provider
of EU-GMP-certified medical cannabis products in over 20 countries.
The company has supported medical trials globally, studying
cannabis for various conditions, including pediatric epilepsy,
cancer-induced nausea, and PTSD.
About Tilray Medical
Tilray Medical is dedicated to transforming lives and fostering
dignity for patients in need through safe and reliable access to a
global portfolio of medical cannabis brands,
including Tilray, Aphria, Broken Coast, Symbios and
Navcora. Tilray grew from being one of the first
companies to become an approved licensed producer of medical
cannabis in Canada to building the first GMP-certified
cannabis production facilities in Europe, first
in Portugal and later in Germany. Today, Tilray
Medical is one of the largest suppliers of medical cannabis to
patients, physicians, hospitals, pharmacies, researchers, and
governments, in 20 countries and across five continents.
For more information on Tilray Medical,
visit Tilray Medical Europe, Tilray Medical
Canada, and Tilray Medical Australia-New
Zealand.
About Tilray Brands
Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a
leading global lifestyle and consumer packaged goods company with
operations in Canada, the United
States, Europe, Australia, and Latin
America that is leading as a transformative force at the nexus
of cannabis, beverage, wellness, and entertainment, elevating lives
through moments of connection. Tilray’s mission is to be a leading
premium lifestyle company with a house of brands and innovative
products that inspire joy and create memorable experiences.
Tilray’s unprecedented platform supports over 40 brands in over 20
countries, including comprehensive cannabis offerings, hemp-based
foods, and craft beverages.
For more information on how we are elevating
lives through moments of connection, visit Tilray.com and
follow @Tilray on all social platforms.
Forward-Looking Statements
Certain statements in this communication that are not historical
facts constitute forward-looking information or forward-looking
statements (together, “forward-looking statements”) under Canadian
securities laws and within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, that are intended to
be subject to the “safe harbor” created by those sections and other
applicable laws. Forward-looking statements can be identified by
words such as “forecast,” “future,” “should,” “could,” “enable,”
“potential,” “contemplate,” “believe,” “anticipate,” “estimate,”
“plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and
the negative of these terms or similar expressions, although not
all forward-looking statements contain these identifying words.
Certain material factors, estimates, goals, projections, or
assumptions were used in drawing the conclusions contained in the
forward-looking statements throughout this communication.
Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses, or current
expectations concerning, among other things: expectations regarding
the performance and scale of the Company, including Tilray Medical;
and the Company’s ability to expand its offering to patients
worldwide, including via Tilray Medical. Many factors could cause
actual results, performance, or achievement to be materially
different from any forward-looking statements, and other risks and
uncertainties not presently known to the Company or that the
Company deems immaterial could also cause actual results or events
to differ materially from those expressed in the forward-looking
statements contained herein. For a more detailed discussion of
these risks and other factors, see the most recently filed annual
information form of Tilray and the Annual Report on Form 10-K (and
other periodic reports filed with the SEC) of Tilray made with the
SEC and available on EDGAR. The forward-looking statements included
in this communication are made as of the date of this communication
and the Company does not undertake any obligation to publicly
update such forward-looking statements to reflect new information,
subsequent events, or otherwise unless required by applicable
securities laws.
For further information:
Tilray Brands: news@tilray.com
Investors: investors@tilray.com
Tilray Brands (TG:2HQ)
Historical Stock Chart
From Nov 2024 to Dec 2024
Tilray Brands (TG:2HQ)
Historical Stock Chart
From Dec 2023 to Dec 2024